C5 and COVID-19: Several reports have found elevated levels of circulating C5a, a potent anaphylatoxin, in patients with severe COVID-19 (3, 5), while deposits of an array of complement constituents have been observed in lung biopsies of patients with evidence of microangiopathic organ injury as well as in those who died from the infection (4, 5).